GTBP vs RCG Comparison

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

RENN Fund Inc is a registered, non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with above-market rates of return through capital appreciation and income by a long-term, value oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities, including convertible and non-convertible debt securities or loans, distressed debt, warrants, preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. To a lesser extent, the fund sells short stocks, exchange-traded funds, and exchange-traded notes. It invests in various industries, including communication services, surgical and medical instruments, oil and gas, etc.